Changes in China-US trade policy are bringing new opportunities to the medical device industry. In September, China's Ministry of Commerce released information on the China-US Trade Council and a reciprocal tariff-reduction framework, with medical devices included on the list of US imports subject to lower tariffs.

Lower tariffs could help reduce costs for some US-made equipment and supplies, benefiting hospitals, third-party laboratories and life sciences research institutions. But the bigger story may be the growing two-way flow of innovation and investment between the two countries.

The United States remains one of China's most important overseas markets for medical devices. In the first half of 2026, China's medical device exports reached $27.1 billion, up 12.4% year on year, according to the China Chamber of Commerce for Import and Export of Medicines and Health Products. Exports to the United States totaled $5.37 billion, accounting for nearly one-fifth of the total. Chinese companies are also expanding their global reach as homegrown innovation drives growth in areas ranging from genetic sequencing and medical imaging to precision instruments.

For US medical technology companies, China is becoming not only a major market, but also an important base for research, manufacturing and innovation. At the 93rd China International Medical Equipment Fair in April, GE HealthCare showcased more than 50 precision medicine innovations, including 12 new product launches and 11 clinical solutions. More than 60% of the exhibits were led by its China-based research teams, while 95% were manufactured in China. The company has also been expanding its local research capabilities, with four innovation centers and more than 1,800 local R&D professionals. The strategy reflects a broader shift toward developing products in China not only for the domestic market, but also for patients and healthcare providers around the world.

Meanwhile, Chinese medical device makers are deepening their presence in the United States. Shanghai-based United Imaging Healthcare established a North American R&D center in Houston in 2013 and later expanded its operations there with a regional headquarters and facilities supporting research, manufacturing and customer services. Its high-end imaging equipment has now been installed in more than 90% of US states, with cumulative installations exceeding 640 units. In the first three quarters, the company's overseas revenue reached 2.996 billion yuan (about $448.99 million), up 50.3% year on year, including more than 700 million yuan (about $104.93 million) from the North American market.

For medical device companies on both sides of the Pacific, each other's markets are no longer just a place for selling products. It is becoming a source of research talent, innovation and industrial expertise, as well as a base for developing products with global reach. Lower tariffs may help facilitate the flow of products, while deeper ties in research, development and global operations could create new opportunities for both sides to compete and to work together.